Summary

This article reviews a phase 3 trial of biologically-based therapy reduction for intermediate risk neuroblastoma in young patients. Also discussed is a final analysis of the Head Start I and II protocols, which looked at outcome sof children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy.